Computational design of PD-L1 small molecule inhibitors for cancer therapy
Drug repurposing opens new avenues in cancer therapy. Drug repurposing, or finding new uses for existing drugs, can substantially reduce drug discovery time and costs. Cheminformatics, genetics, and systems biology advances enable repositioning drugs. Clinical usage of PD-1/PD-L1 blocking has been approved because of its efficacy in improving prognosis in select groups. The PD-1/PD-L1 axis was considered to represent a mechanism for tumour evasion of host tumour antigen-specific T-cell immunity in early preclinical research. The expression of PD-L1 in cancer cells causes T lymphocytes to become exhausted by transmitting a co-inhibitory signal. A better understanding of how PD-L1 is regulated in cancer cells could lead to new therapeutic options. In this view, the study was aimed to repurpose the existing FDA-approved drugs as a potential PD-L1 inhibitor through e-Pharmacophore modelling, molecular docking and dynamic simulation. e-Pharmacophore screening retrieved 324 FDA-approved medications with the fitness score ≥ 1. The top 10-docked FDA candidates were compared with IN-35 (Clinical trial candidate) for its interaction pattern with critical amino acid residues. Mirabegron and Indacaterol exhibited a greater affinity for PD-L1 with docking scores of − 9.213 kcal $ mol^{−1} $ and − 8.023 kcal $ mol^{−1} $, respectively. Mirabegron retain interactions at all three major hotspots in the PD-L1 dimer interface similar to IN-35. MM-GBSA analyses indicated that Mirabegron uses less energy to create a more stable complex and retains all of the inhibitor’s positive interactions found in clinical trial ligand IN-35. Molecular dynamics simulation analysis of the Mirabegron complex showed a similar pattern of deviation in correlation with IN-35, and it retains the interaction with the active key amino acids throughout the simulation time. Our present study has shown Mirabegron as a powerful inhibitor of PD-L1 expression in cancer cells using a drug-repurposing screen. Graphical abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Molecular diversity - 27(2022), 4 vom: 25. Aug., Seite 1633-1644 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chandrasekaran, Jaikanth [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11030-022-10516-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144942196 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144942196 | ||
| 003 | DE-627 | ||
| 005 | 20240118101858.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11030-022-10516-3 |2 doi | |
| 035 | |a (DE-627)OLC2144942196 | ||
| 035 | |a (DE-He213)s11030-022-10516-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 100 | 1 | |a Chandrasekaran, Jaikanth |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Computational design of PD-L1 small molecule inhibitors for cancer therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Drug repurposing opens new avenues in cancer therapy. Drug repurposing, or finding new uses for existing drugs, can substantially reduce drug discovery time and costs. Cheminformatics, genetics, and systems biology advances enable repositioning drugs. Clinical usage of PD-1/PD-L1 blocking has been approved because of its efficacy in improving prognosis in select groups. The PD-1/PD-L1 axis was considered to represent a mechanism for tumour evasion of host tumour antigen-specific T-cell immunity in early preclinical research. The expression of PD-L1 in cancer cells causes T lymphocytes to become exhausted by transmitting a co-inhibitory signal. A better understanding of how PD-L1 is regulated in cancer cells could lead to new therapeutic options. In this view, the study was aimed to repurpose the existing FDA-approved drugs as a potential PD-L1 inhibitor through e-Pharmacophore modelling, molecular docking and dynamic simulation. e-Pharmacophore screening retrieved 324 FDA-approved medications with the fitness score ≥ 1. The top 10-docked FDA candidates were compared with IN-35 (Clinical trial candidate) for its interaction pattern with critical amino acid residues. Mirabegron and Indacaterol exhibited a greater affinity for PD-L1 with docking scores of − 9.213 kcal $ mol^{−1} $ and − 8.023 kcal $ mol^{−1} $, respectively. Mirabegron retain interactions at all three major hotspots in the PD-L1 dimer interface similar to IN-35. MM-GBSA analyses indicated that Mirabegron uses less energy to create a more stable complex and retains all of the inhibitor’s positive interactions found in clinical trial ligand IN-35. Molecular dynamics simulation analysis of the Mirabegron complex showed a similar pattern of deviation in correlation with IN-35, and it retains the interaction with the active key amino acids throughout the simulation time. Our present study has shown Mirabegron as a powerful inhibitor of PD-L1 expression in cancer cells using a drug-repurposing screen. Graphical abstract | ||
| 650 | 4 | |a PD-1/PD-L1 | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a e-Pharmacophore | |
| 650 | 4 | |a Repurposing | |
| 650 | 4 | |a Docking | |
| 650 | 4 | |a Dynamic simulation | |
| 700 | 1 | |a Elumalai, Senthilkumar |4 aut | |
| 700 | 1 | |a Murugesan, Vidya |4 aut | |
| 700 | 1 | |a Kunjiappan, Selvaraj |4 aut | |
| 700 | 1 | |a Pavadai, Parasuraman |4 aut | |
| 700 | 1 | |a Theivendren, Panneerselvam |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular diversity |d Springer International Publishing, 1995 |g 27(2022), 4 vom: 25. Aug., Seite 1633-1644 |w (DE-627)225977672 |w (DE-600)1376507-3 |w (DE-576)9225977670 |x 1381-1991 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:4 |g day:25 |g month:08 |g pages:1633-1644 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11030-022-10516-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 4 |b 25 |c 08 |h 1633-1644 | ||